Lilly's Zepbound gains FDA approval for OSA in adults with obesity
FDA approves Lilly's Zepbound for moderate-to-severe obstructive sleep apnoea in obese adults, the first prescription medication for the condition. Zepbound, used with diet and exercise, significantly reduces breathing disruptions and aids long-term weight loss, with 42-50% of patients achieving remission or mild OSA.
Related Clinical Trials
Related News
Lilly's Zepbound gains FDA approval for OSA in adults with obesity
FDA approves Lilly's Zepbound for moderate-to-severe obstructive sleep apnoea in obese adults, the first prescription medication for the condition. Zepbound, used with diet and exercise, significantly reduces breathing disruptions and aids long-term weight loss, with 42-50% of patients achieving remission or mild OSA.